JMP Securities analyst Silvan Tuerkcan initiated coverage of enGene (ENGN) with an Outperform rating and $18 price target enGene is a clinical-stage biotechnology company focused on developing ...
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback